Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of GP40081 vs NovoMix 30 in T2DM
NCT04226105Phase 3Unknown
- Sponsor
- Geropharm
- Start
- Jan 2020
- Primary completion
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of biphasic insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Geropharm. Primary endpoint: Immunogenicity (Timeframe: 26 weeks). Status: unknown.
02
Drugs
biphasic insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04226105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04226105.